A Systematic Literature Review of Current Therapeutic Approaches for COVID-19 Patients

References (67)

1. 1 Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China [DOI]
2. 2 Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study [DOI]
3. 3 Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding [DOI]
4. 4 Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study [DOI]
5. 5 Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro [DOI]
6. 6 First Case of 2019 Novel Coronavirus in the United States [DOI]
7. 7 Clinical characteristics of 140 patients infected with SARS‐CoV‐2 in Wuhan, China [DOI]
8. 8 Antimicrobial agents and chemotherapy—1969 [DOI]
9. 9 Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series [DOI]
10. 10 Chloroquine is a potent inhibitor of SARS coronavirus infection and spread [DOI]
11. 11 Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV [DOI]
12. 12 Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings [DOI]
13. 13 Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses [DOI]
14. 14 Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys [DOI]
15. 15 Clinical Features and Short-term Outcomes of 144 Patients With SARS in the Greater Toronto Area [DOI]
16. 16 Virus-encoded proteinases and proteolytic processing in the Nidovirales [DOI]
17. 17 Use of convalescent plasma therapy in SARS patients in Hong Kong [DOI]
18. 18 Screening of an FDA-Approved Compound Library Identifies Four Small-Molecule Inhibitors of Middle East Respiratory Syndrome Coronavirus Replication in Cell Culture [DOI]
19. 19 Ivermectin is a specific inhibitor of importin α/β-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus [DOI]
20. 20 Case of the Index Patient Who Caused Tertiary Transmission of Coronavirus Disease 2019 in Korea: the Application of Lopinavir/Ritonavir for the Treatment of COVID-19 Pneumonia Monitored by Quantitative RT-PCR [DOI]
21. 21 New insights into the antiviral effects of chloroquine [DOI]
22. 22 Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment [DOI]
23. 23 Small molecules targeting severe acute respiratory syndrome human coronavirus [DOI]
24. 24 A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus—A possible reference for coronavirus disease‐19 treatment option [DOI]
25. 25 Treatment of SARS with human interferons [DOI]
26. 26 Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV–infected rhesus macaques [DOI]
27. 27 Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study.
28. 28 Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients [DOI]
29. 29 Pegylated interferon-α protects type 1 pneumocytes against SARS coronavirus infection in macaques [DOI]
30. 30 MERS, SARS, and Ebola: The Role of Super-Spreaders in Infectious Disease [DOI]
31. 31 Anti-malaria drug chloroquine is highly effective in treating avian influenza A H5N1 virus infection in an animal model [DOI]
32. 32 Severe Acute Respiratory Syndrome (SARS) in Singapore: Clinical Features of Index Patient and Initial Contacts [DOI]
33. 33 Molecular model of SARS coronavirus polymerase: implications for biochemical functions and drug design [DOI]
34. 34 Broad-spectrum coronavirus antiviral drug discovery [DOI]
35. 35 Severe Acute Respiratory Syndrome–Related Coronavirus Is Inhibited by Interferon‐α [DOI]
36. 36 Environmental Contamination and Viral Shedding in MERS Patients During MERS-CoV Outbreak in South Korea [DOI]
37. 37 An AlphaScreen®-Based Assay for High-Throughput Screening for Specific Inhibitors of Nuclear Import [DOI]
38. 38 Molecular dynamic simulations analysis of ritronavir and lopinavir as SARS-CoV 3CLpro inhibitors [DOI]
39. 39 The course of clinical diagnosis and treatment of a case infected with coronavirus disease 2019 [DOI]
40. 40 Emerging respiratory infections: The infectious disease pathology of SARS, MERS, pandemic influenza, and Legionella [DOI]
41. 41 Emergence of MERS-CoV in the Middle East: Origins, Transmission, Treatment, and Perspectives [DOI]
42. 42 Clinical Features and Treatment of 2019-nCov Pneumonia Patients in Wuhan: Report of A Couple Cases [DOI]
43. 43 Safe and Sensitive Antiviral Screening Platform Based on Recombinant Human Coronavirus OC43 Expressing the Luciferase Reporter Gene [DOI]
44. 44 Treatment of SARS with human interferons [DOI]
45. 45 A realistic two-strain model for MERS-CoV infection uncovers the high risk for epidemic propagation [DOI]
46. 46 Middle East Respiratory Syndrome [DOI]
47. 47 Clinical use of lopinavir/ritonavir in a salvage therapy setting [DOI]
48. 48 Deducing the Crystal Structure of MERS-CoV Helicase [DOI]
49. 49 Single-cell RNA expression profiling of ACE2, the receptor of SARS-CoV-2 [DOI]
50. 50 SARS-CoV-2 and SARS-CoV Spike-RBD Structure and Receptor Binding Comparison and Potential Implications on Neutralizing Antibody and Vaccine Development [DOI]
51. 51 The proximal origin of SARS-CoV-2 [DOI]
52. 52 Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target [DOI]
53. 53 The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro [DOI]
54. 54 Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2 [DOI]
55. 55 Functional exhaustion of antiviral lymphocytes in COVID-19 patients [DOI]
56. 56 Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine [DOI]
57. 57 Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein [DOI]
58. 58 Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro [DOI]
59. 59 Favipiravir Versus Arbidol for Clinical Recovery Rate in Moderate and Severe Adult COVID-19 Patients: A Prospective, Multicenter, Open-Label, Randomized Controlled Clinical Trial [DOI]
60. 60 A Case of 2019 Novel Coronavirus in a Pregnant Woman With Preterm Delivery [DOI]
61. 61 First case of Coronavirus Disease 2019 (COVID-19) pneumonia in Taiwan [DOI]
62. 62 Structural Basis of the Potential Binding Mechanism of Remdesivir to SARS-CoV-2 RNA-Dependent RNA Polymerase [DOI]
63. 63 Thalidomide Combined with Low-dose Glucocorticoid in the Treatment of COVID-19 Pneumonia
64. 64 The PDZ-binding Motif of SARS-CoV Envelope Protein Induces Cancerization and Poor Prognosis of Lung Adenocarcinoma
65. 65 La certeza de lo impredecible: Cultura Educación y Sociedad en tiempos de COVID19
66. 66 British Journal of Clinical Pharmacology [DOI]
67. 67 A Current Emerging Respiratory Infection: Epidemiological and Clinical Characteristics, Diagnosis and Treatments of COVID-19 [DOI]

Cited by 17

Showing 8 of 17 known citations — external sources report more than can currently be individually listed.

Related research

• Covid-2019:“A Microbiological Monster” — shares topic coverage
• COVID 19 Disease Caused by Coronavirus 2 (SARS-CoV-2) (Severe Acute Respiratory Syndrome) — shares topic coverage
• Using Ultraviolet A to Check Inanimate Objects for Thorough Cleanliness during COVID-19 Pandemic — shares topic coverage
• The Evaluation of Biochemical Parameters in Positive COVID-19 RealTime PCR Patients: A Retrospective Study — shares topic coverage
• Characteristics of the New Coronavirus Named SARS-CoV-2 Responsible for an Infection Called Coronavirus Disease 2019 (COVID-19) — shares topic coverage